Skip to main content
SpringerLink
Log in

Immunglobuline bei Antikörpermangelsyndrom

Einsatz auch bei Sepsis und anderen Indikationen?

Immunoglobulins in primary antibody deficiency

Should they also be used in sepsis and other indications?

  • Arzneimitteltherapie
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Immunglobuline (Antikörper) sind Blutprodukte, die aus dem Plasma gesunder Spender gewonnen werden. Der therapeutische Nutzen von polyvalenten Immunglobulinen ist unter anderem bei primären Immundefekten, bei der idiopathischen thrombozytopenischen Purpura (ITP) und dem Guillain-Barré-Syndrom (GBS) nachgewiesen. Ein therapeutischer Einsatz bei der Sepsis hingegen wird kontrovers diskutiert. In dieser Übersicht wird anhand der aktuellen Studienlage der Stellenwert der kostenintensiven Therapie von Immunglobulinen bei unterschiedlichen Krankheitsbildern diskutiert. Der Schwerpunkt liegt hierbei auf dem Einsatz von Immunglobulinen bei Sepsis und septischem Schock.

Abstract

Immunoglobulin is a blood product prepared from the plasma of healthy donors. The therapeutic use of polyvalent immunoglobulins is an established therapy in primary antibody deficiencies, in idiopathic thrombocytopenic purpura (ITP) and in Guillain-Barré syndrome. However, there is an ongoing debate about the efficacy of polyvalent immunoglobulins as adjunctive therapy for sepsis. The paper presented here critically discusses the modern studies investigating the use of immunoglobulins in different diseases. The main focus is the use of immunoglobulins in patients with sepsis or septic shock.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Alejandria MM, Lansang MA, Dans LF, Mantaring JB (2002) Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev CD001090

  2. Bass EB, Powe NR, Goodman SN et al. (1993) Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 12: 273–282

    PubMed  CAS  Google Scholar 

  3. Berger D, Schleich S, Seidelmann M, Beger H (1993) Antiendotoxic therapy with polyclonal and polyvalent immunoglobulins: in vitro and in vivo studies. In: Faist E, Meakins J, Schildberg FW (eds) Host defense dysfunction in trauma, shock and sepsis. Springer, Berlin Heidelberg New York, pp 1163–1174

  4. Borte M, Oertelt C, Hogy B (2005) Behandlung von Patienten mit primären Antikörpermangelsyndromen in Deutschland. Klin Padiatr 217: 276–280

    Article  PubMed  CAS  Google Scholar 

  5. Bundesärztekammer (2003) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Deutscher Ärzte Verlag, Köln

  6. Cordonnier C, Chevret S, Legrand M et al. (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139: 8–18

    PubMed  CAS  Google Scholar 

  7. Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993–2000

    Article  PubMed  CAS  Google Scholar 

  8. Darenberg J, Ihendyane N, Sjolin J et al. (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37: 333–340

    Article  PubMed  CAS  Google Scholar 

  9. Federico P, Zochodne DW, Hahn AF et al. (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55: 1256–1262

    PubMed  CAS  Google Scholar 

  10. Fehr J, Hofmann V, Kappeler U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306: 1254–1258

    Article  PubMed  CAS  Google Scholar 

  11. Gadola S, Salzer U, Schultz H, Grimbacher B (2004) Adult manifestierende primäre Immundefizienzen. Internist (Berl) 45: 912–922

  12. Garbett ND, Munro CS, Cole PJ (1989) Opsonic activity of a new intravenous immunoglobulin preparation: pentaglobin compared with sandoglobulin. Clin Exp Immunol 76: 8–12

    PubMed  CAS  Google Scholar 

  13. Gold R, Stangel M, Dalakas MC (2007) Drug insight: the use of intravenous immunoglobulin in neurology – therapeutic considerations and practical issues. Nat Clin Pract Neurol 3: 36–44

    Article  PubMed  CAS  Google Scholar 

  14. Gray O, McDonnell GV, Forbes RB (2003) Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev CD002936

  15. Guglielmo BJ, Wong-Beringer A, Linker CA (1994) Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 13: 499–510

    PubMed  CAS  Google Scholar 

  16. Hallek M, Eichhorst B, Dreger P (2006) Chronische lymphatische Leukämie. Leitlinien: Empfehlungen der DGHO für die Diagnostik und Therapie, Online-Publikation: http://www.dgho.de/_cmsdata/_file/file_178.pdf

  17. Heiken H, Schmidt RE (2003) Indikationen für den Einsatz von Immunglobulinen. Dtsch Med Wochenschr 128: 1665–1669

    Article  PubMed  CAS  Google Scholar 

  18. Hentrich M, Fehnle K, Ostermann H et al. (2006) IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 34: 1319–1325

    Article  PubMed  CAS  Google Scholar 

  19. Hiller E, Matzdorff A, Fischer JT (2005) Thrombozytopenien. Leitlinien: Empfehlungen der DGHO für die Diagnostik und Therapie, Online-Publikation: http://www.dgho.de/_cmsdata/_file/file_129.pdf

  20. Hughes RA, Raphael JC, Swan AV, van Doorn PA (2006) Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev CD002063

  21. Kaul R, McGeer A, Norrby-Teglund A et al. (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome – a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28: 800–807

    PubMed  CAS  Google Scholar 

  22. Ferencik M, Rovensky J, Matha V, Jensen-Jarolim E (2005) Wörterbuch Allergologie und Immunologie. Springer, Wien NewYork

  23. Kreymann KG, de Heer G, Nierhaus A, Kluge S (2007) Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med (in press)

  24. Leger JM, Chassande B, Musset L et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124: 145–153

    Article  PubMed  CAS  Google Scholar 

  25. Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68: 355–361

    Article  PubMed  CAS  Google Scholar 

  26. Norrby-Teglund A, Basma H, Andersson J et al. (1998) Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 26: 631–638

    PubMed  CAS  Google Scholar 

  27. Norrby-Teglund A, Kaul R, Low DE et al. (1996) Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 156: 3057–3064

    PubMed  CAS  Google Scholar 

  28. Oates-Whitehead RM, Baumer JH, Haines L et al. (2003) Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev CD004000

  29. Oesser S, Schulze C, Seifert J (1999) Protective capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia. Res Exp Med (Berl) 198: 325–339

    Article  Google Scholar 

  30. Pildal J, Gotzsche PC (2004) Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 39: 38–46

    Article  PubMed  CAS  Google Scholar 

  31. Rieben R, Roos A, Muizert Y et al. (1999) Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 93: 942–951

    PubMed  CAS  Google Scholar 

  32. Schedel I, Dreikhausen U, Nentwig B et al. (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19: 1104–1113

    Article  PubMed  CAS  Google Scholar 

  33. Spornraft-Ragaller P, Theilen H, Gottschlich GS, Ragaller M (2006) Behandlung der toxischen epidermalen Nekrolyse. Erfahrungen bei 9 Patienten unter Berücksichtigung von intravenösen Immunglobulinen. Hautarzt 57: 185–190, 192

    Article  PubMed  CAS  Google Scholar 

  34. Stangel M, Gold R (2004) Einsatz von i.v. Immunglobulinen in der Neurologie. Ein evidenzbasierter Konsens. Nervenarzt 75: 801–815

    Article  PubMed  CAS  Google Scholar 

  35. Trautmann M, Held TK, Susa M et al. (1998) Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol 111: 81–90

    Article  PubMed  CAS  Google Scholar 

  36. Van den Berg LH, Kerkhoff H, Oey PL et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59: 248–252

    Article  Google Scholar 

  37. Werdan K (2005) Prävention und Therapie mit Immunglobulinen – Gesichertes und weniger Gesichertes. In: Werdan K, Schuster HP, Müller-Werdan U (Hrsg) Sepsis und MODS. Springer, Berlin Heidelberg New York Tokyo

  38. Werdan K (2006) Immunoglobulin treatment in sepsis – is the answer „no“? Crit Care Med 34: 1542–1544

    Article  PubMed  Google Scholar 

  39. Werdan K, Pilz G, the SBITS Study Group (1997) Polyvalent immune globulins. Shock 7 (Suppl): A5: 1918

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Der korrespondierende Autor hat in den vergangenen Jahren Vortragshonorare von den Firmen Biotest und Sandoz erhalten.

Author information

Authors and Affiliations

  1. Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    S. Kluge, G. de Heer, A. Nierhaus &  G. Kreymann

Authors
  1. S. Kluge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. de Heer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Nierhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Kreymann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Kreymann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kluge, S., de Heer, G., Nierhaus, A. et al. Immunglobuline bei Antikörpermangelsyndrom. Internist 48, 1297–1304 (2007). https://doi.org/10.1007/s00108-007-1933-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-007-1933-7

Schlüsselwörter

Keywords

Search

Navigation